Connor Clark & Lunn Investment Management Ltd. reduced its stake in Krystal Biotech, Inc. (NASDAQ:KRYS – Free Report) by 57.9% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 6,990 shares of the company’s stock after selling 9,601 shares during the quarter. Connor Clark & Lunn Investment Management Ltd.’s holdings in Krystal Biotech were worth $560,000 at the end of the most recent quarter.
Other large investors also recently added to or reduced their stakes in the company. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. grew its holdings in Krystal Biotech by 7.0% in the 1st quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 3,476 shares of the company’s stock valued at $278,000 after buying an additional 227 shares in the last quarter. Avoro Capital Advisors LLC grew its holdings in Krystal Biotech by 10.6% in the 4th quarter. Avoro Capital Advisors LLC now owns 1,410,000 shares of the company’s stock valued at $111,700,000 after buying an additional 135,000 shares in the last quarter. Stonnington Group LLC purchased a new stake in Krystal Biotech in the 1st quarter valued at $276,000. Braidwell LP purchased a new stake in Krystal Biotech in the 4th quarter valued at $28,365,000. Finally, Victory Capital Management Inc. grew its holdings in Krystal Biotech by 11.8% in the 4th quarter. Victory Capital Management Inc. now owns 339,331 shares of the company’s stock valued at $26,882,000 after buying an additional 35,732 shares in the last quarter. 82.96% of the stock is currently owned by hedge funds and other institutional investors.
Krystal Biotech Trading Down 2.0 %
KRYS opened at $124.16 on Friday. The stock’s 50-day moving average price is $121.53 and its 200 day moving average price is $100.81. Krystal Biotech, Inc. has a 12-month low of $61.11 and a 12-month high of $131.80. The firm has a market cap of $3.48 billion, a price-to-earnings ratio of -22.87 and a beta of 0.81.
Analyst Ratings Changes
Several analysts have issued reports on the company. Stifel Nicolaus upped their target price on Krystal Biotech from $102.00 to $145.00 in a report on Wednesday, May 24th. Guggenheim upped their price target on Krystal Biotech from $101.00 to $130.00 in a research note on Monday, May 22nd. Bank of America upped their price target on Krystal Biotech from $105.00 to $118.00 in a research note on Sunday, May 21st. HC Wainwright reaffirmed a “buy” rating and issued a $139.00 price target on shares of Krystal Biotech in a research note on Monday, August 7th. Finally, Chardan Capital upped their price target on Krystal Biotech from $148.00 to $153.00 and gave the company a “buy” rating in a research note on Monday, August 7th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $134.83.
Check Out Our Latest Stock Analysis on Krystal Biotech
Insider Buying and Selling
In related news, insider Andrew C. Orth sold 12,500 shares of the stock in a transaction dated Friday, June 9th. The stock was sold at an average price of $128.61, for a total transaction of $1,607,625.00. Following the transaction, the insider now owns 100 shares of the company’s stock, valued at approximately $12,861. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction dated Wednesday, May 31st. The stock was sold at an average price of $116.16, for a total value of $2,904,000.00. Following the sale, the insider now owns 1,624,206 shares of the company’s stock, valued at approximately $188,667,768.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Andrew C. Orth sold 12,500 shares of the stock in a transaction dated Friday, June 9th. The shares were sold at an average price of $128.61, for a total value of $1,607,625.00. Following the completion of the sale, the insider now directly owns 100 shares in the company, valued at approximately $12,861. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 68,565 shares of company stock valued at $8,491,362. Corporate insiders own 17.00% of the company’s stock.
Krystal Biotech Company Profile
Krystal Biotech, Inc, a biotechnology company, develops and commercializes genetic medicines for patients with rare diseases in the United States. It develops beremagene geperpavec (B-VEC) for dystrophic epidermolysis bullosa; KB105 for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for netherton syndrome; and KB407 for Cystic Fibrosis.
Featured Stories
- Five stocks we like better than Krystal Biotech
- How to Invest in Mining Stocks
- Can These 2 Industrial Titans Extend Double-Digit YTD Growth?
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- How to Profit from These 3 Membership Club Stocks’ Strengths
- How to Invest in Lithium and Lithium Stocks
- 5 Best High-Yield Dividend Stocks for Any Economic Climate
Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
